Institutional players now control 84.58% of the stock
In the quiet machinery of capital markets, Keysight Technologies has drawn the sustained attention of institutional investors who collectively now hold nearly 85% of its outstanding shares — a concentration that reflects not mere speculation, but a considered wager on the durability of precision measurement in an increasingly complex technological world. Through the first half of 2025, hedge funds and investment managers expanded their positions as the company delivered earnings that exceeded expectations, grew revenue by double digits, and offered guidance that outpaced Wall Street's own forecasts. The story unfolding around Keysight is one familiar to market observers: when results align with narrative, capital tends to follow.
- A wave of institutional buying swept through Keysight's shareholder registry in Q1 and Q2 2025, with some funds more than doubling their positions in a matter of months.
- The urgency behind these moves was validated in August when Keysight reported Q2 earnings that beat estimates, with revenue surging 11.1% year-over-year to $1.35 billion.
- Management's own full-year guidance of $7.09 per share stands well above Wall Street's consensus of $6.32, creating a tension between analyst caution and corporate confidence.
- JPMorgan raised its price target to $200 and Wall Street Zen upgraded to strong-buy, while the stock trades near $170 — leaving a visible gap that bulls believe will close.
- Insider sales by the CFO and a senior vice president introduced a note of caution, though their combined ownership is minimal against the institutional tide pressing in the opposite direction.
Keysight Technologies has become a focal point for institutional capital in 2025. Across the first and second quarters, a succession of hedge funds and investment managers quietly built or expanded their positions in the electronic test and measurement company. GAMMA Investing led the charge with a 142.8% increase in its holdings, while Praxis Investment Management grew its stake by nearly half and Foyston Gordon & Payne added over 6,000 shares to reach nearly 60,000. Altogether, institutional investors now control 84.58% of Keysight's outstanding stock — a figure that signals broad, deliberate conviction.
The numbers behind that conviction are tangible. Keysight's second-quarter earnings came in at $1.72 per share, a nickel above analyst expectations, while revenue of $1.35 billion exceeded forecasts and marked 11.1% growth over the prior year. The company's balance sheet remains healthy, with a current ratio above 3.5 and a modest debt-to-equity ratio of 0.45. Management guided for full-year 2025 earnings of $7.09 per share — a figure that sits meaningfully above the Street's consensus of $6.32, hinting at further upside surprises.
Analyst sentiment has tracked the momentum. JPMorgan raised its price target to $200 in July, and Wall Street Zen upgraded the stock to strong-buy in early September. The consensus target of $187.38 implies roughly 10% upside from the stock's mid-September price of $170.56. Barclays and Bank of America also maintained constructive stances, even as they adjusted their targets modestly.
Not every signal points in the same direction. CFO Neil Dougherty and Senior Vice President Ingrid Estrada both sold shares in June, trimming their personal stakes by roughly 9% and 8% respectively. These transactions are routine in character, and insiders collectively hold less than 1% of the company — meaning their sales register as little more than a footnote against the broader institutional accumulation. For now, the weight of capital and analyst opinion leans toward the view that Keysight's best chapters may still lie ahead.
Keysight Technologies has become a magnet for institutional money. In the second quarter alone, Kera Capital Partners established a new position worth roughly $247,000, purchasing 1,506 shares of the electronic test and measurement company. But Kera was hardly alone. Across the first and second quarters of 2025, a parade of hedge funds and investment managers quietly expanded their stakes, each betting that the company's momentum would continue.
Praxis Investment Management nearly doubled down, growing its holding by 45.8% to reach 6,371 shares valued at $954,000. GAMMA Investing made the most aggressive move, more than doubling its position with a 142.8% increase that left it owning 5,012 shares. Foyston Gordon & Payne, already a substantial holder, added another 6,186 shares for an 11.5% boost, bringing its total to nearly 60,000 shares worth $8.96 million. Allspring Global Investments and Wealth Enhancement Advisory Services also increased their stakes, though more modestly. Collectively, these institutional players now control 84.58% of Keysight's outstanding stock—a concentration that speaks to confidence in the company's direction.
That confidence appears grounded in results. In August, Keysight reported second-quarter earnings of $1.72 per share, beating analyst expectations by a nickel. Revenue climbed to $1.35 billion, up 11.1% from the same quarter a year prior and exceeding the consensus forecast of $1.32 billion. The company's net margin held steady at 10.36%, while return on equity reached 19.53%. Management guided for fourth-quarter earnings between $1.79 and $1.85 per share, with full-year 2025 guidance at $7.09 per share. Wall Street's consensus forecast sits at $6.32 for the current fiscal year, suggesting the company may yet surprise to the upside.
The stock itself has reflected this optimism. Trading at $170.56 as of mid-September, Keysight sits near the upper end of its 12-month range, which spans from $121.43 to $186.20. The company carries a price-to-earnings ratio of 54.32 and a market capitalization of $29.31 billion. Its balance sheet remains solid: a current ratio of 3.59, a quick ratio of 2.94, and a debt-to-equity ratio of just 0.45. The stock's 50-day moving average of $164.74 sits comfortably below its 200-day average of $156.98, a technical setup that some traders read as bullish.
Analysts have taken notice. JPMorgan Chase raised its price target from $177 to $200 in mid-July, assigning an overweight rating. Barclays, while trimming its target slightly from $200 to $195, maintained an overweight stance. Wall Street Zen upgraded the stock from buy to strong-buy in early September. Bank of America nudged its target upward from $175 to $179, though it assigned a neutral rating. Across seven analysts offering buy ratings and one offering a hold, the consensus target price stands at $187.38—suggesting roughly 10% upside from current levels.
Insiders have been sellers, though modestly. In June, CFO Neil Dougherty sold 12,215 shares at an average price of $164.60, netting roughly $2 million and reducing his stake by 9.58%. Senior Vice President Ingrid Estrada sold 10,000 shares at $158.97, trimming her position by 8.43%. These transactions are routine and do not suggest alarm; insiders collectively own just 0.61% of the company, so their sales carry limited weight against the institutional buying tide.
Keysight operates in electronic design and test solutions across communications, aerospace, defense, automotive, energy, semiconductor, and education sectors. The company is split into two operating segments: Communications Solutions Group and Electronic Industrial Solutions Group. It serves customers across the Americas, Europe, and Asia Pacific. For investors watching the stock, the question now is whether the analyst upgrades and institutional accumulation will push the stock toward the $200 target or whether current valuations already price in the expected growth.
Citações Notáveis
JPMorgan Chase raised price target from $177 to $200 with an overweight rating— JPMorgan Chase & Co.
Wall Street Zen upgraded Keysight from buy to strong-buy rating— Wall Street Zen
A Conversa do Hearth Outra perspectiva sobre a história
Why are so many hedge funds buying Keysight right now? What changed?
The earnings beat in August seems to have been the catalyst. They topped expectations on both the bottom and top line, and the guidance was solid. But it's not just one quarter—there's a pattern of institutional accumulation across multiple quarters, which suggests these funds see something structural improving.
The stock trades at a P/E of 54. That's not cheap. What justifies that valuation?
Fair question. The P/E is elevated, but the company is growing revenue at 11% year-over-year and has strong margins. The return on equity is nearly 20%. For a company in semiconductors and test equipment—sectors that are cyclical but currently in favor—that growth rate can support a premium multiple, especially if analysts think it can sustain or accelerate.
JPMorgan raised the target to $200, but the stock is at $170. Is that a realistic target or just optimism?
It's about 10% upside from here, which is modest for a Wall Street target. The consensus across analysts is $187, so JPMorgan is the most bullish. Whether it gets there depends on execution—whether they can keep beating estimates and whether the end markets they serve stay healthy.
The insiders sold shares. Doesn't that worry you?
Not particularly. The CFO and an SVP each trimmed positions by around 8-9%, which is routine portfolio rebalancing. They still own meaningful stakes. The real signal is that institutional ownership is 84.58%—that's where the money is flowing.
What could go wrong?
Cyclical downturns in semiconductors or communications. A slowdown in capital spending by their customers. Valuation compression if growth disappoints. The stock is priced for continued execution, so any stumble would hurt. But right now, the momentum is clearly positive.